Bioavailability of vinpocetine and interference of the time of application with food intake.
In a pilot study based on an open cross-over design involving four phases, the relative bioavailability of the eburnamenine derivative vinpocetine (CAS 42971-09-5) was investigated in 8 healthy volunteers in relation to different times of drug administration relative to food intake. The substance was applied orally as 10 mg film tablets. The areas under the plasma concentration-time curves (AUC) amounted to 27.3 +/- 18.1 ng.h/ml (fasting) and 42.8 +/- 27.4 up to 54.3 +/- 38.4 ng.h/ml (non-fasting, intake before and after meal, resp.). The relative bioavailability under non-fasting conditions was found to be approx. 60 to 100% higher than under fasting conditions.
Lohmann
A
A
Pharmacokinetics Department, Thiemann Arzneimittel GmbH, Waltrop, Fed. Rep. of Germany.
Dingler
E
E
Sommer
W
W
Schaffler
K
K
Wober
W
W
Schmidt
W
W
D000328:Adult; D001682:Biological Availability; D004435:Eating; D005260:Female; D006801:Humans; D008297:Male; D014748:Vinca Alkaloids / Q000008:administration & dosage / Q000493:pharmacokinetics*
D014748:Vinca Alkaloids; C013983:vinpocetine